DE60323231D1 - Verkürzte tau proteine - Google Patents

Verkürzte tau proteine

Info

Publication number
DE60323231D1
DE60323231D1 DE60323231T DE60323231T DE60323231D1 DE 60323231 D1 DE60323231 D1 DE 60323231D1 DE 60323231 T DE60323231 T DE 60323231T DE 60323231 T DE60323231 T DE 60323231T DE 60323231 D1 DE60323231 D1 DE 60323231D1
Authority
DE
Germany
Prior art keywords
molecules
amino acids
terminal amino
tau
detectable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323231T
Other languages
English (en)
Inventor
Eva Kontsekova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axon Neuroscience Forschungs- und Entwicklungs GmbH
Axon Neuroscience SE
Original Assignee
Axon Neuroscience Forschungs- und Entwicklungs GmbH
Axon Neuroscience SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Forschungs- und Entwicklungs GmbH, Axon Neuroscience SE filed Critical Axon Neuroscience Forschungs- und Entwicklungs GmbH
Application granted granted Critical
Publication of DE60323231D1 publication Critical patent/DE60323231D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE60323231T 2002-07-12 2003-07-09 Verkürzte tau proteine Expired - Lifetime DE60323231D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT10532002 2002-07-12
PCT/EP2003/007389 WO2004007547A2 (en) 2002-07-12 2003-07-09 Truncated tau proteins

Publications (1)

Publication Number Publication Date
DE60323231D1 true DE60323231D1 (de) 2008-10-09

Family

ID=30120907

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60320258T Expired - Lifetime DE60320258T2 (de) 2002-07-12 2003-07-09 Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
DE60323231T Expired - Lifetime DE60323231D1 (de) 2002-07-12 2003-07-09 Verkürzte tau proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60320258T Expired - Lifetime DE60320258T2 (de) 2002-07-12 2003-07-09 Transgenes tier welches das trunkierte alzheimer tau protein exprimiert

Country Status (10)

Country Link
US (5) US8288608B2 (de)
EP (3) EP1521831B1 (de)
JP (3) JP4414332B2 (de)
CN (2) CN100572392C (de)
AT (2) ATE391781T1 (de)
AU (2) AU2003246664B2 (de)
DE (2) DE60320258T2 (de)
DK (2) DK1521774T3 (de)
ES (2) ES2311734T3 (de)
WO (2) WO2004007722A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1521774T3 (da) * 2002-07-12 2008-10-27 Axon Neuroscience Trunkerede Tau-proteiner
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7609947B2 (en) 2004-09-10 2009-10-27 Panasonic Corporation Method and apparatus for coordinating playback from multiple video sources
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
KR100734815B1 (ko) 2006-02-15 2007-07-09 대한민국 Ｈｔａｕ24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
CN102058619A (zh) * 2010-12-08 2011-05-18 山西医科大学 一种阿尔茨海默病复合动物模型的制备方法
AU2011352333B2 (en) * 2010-12-31 2016-12-08 Zeus Scientific, Inc. Improved methods for determining cell viability using molecular nucleic acid-based techniques
EP2670434B1 (de) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Behandlung von tauopathien
WO2012162179A1 (en) 2011-05-20 2012-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
HUE036177T2 (hu) 2011-09-19 2018-06-28 Axon Neuroscience Se TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
KR102076384B1 (ko) 2012-08-16 2020-02-11 아이피어리언 인코포레이티드 타우병증을 치료하는 방법
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3104870A4 (de) 2014-02-14 2017-09-13 Ipierian, Inc. Tau-peptide, anti-tau-antikörper und verfahren zur verwendung davon
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
HUE053239T2 (hu) 2014-11-19 2021-06-28 Axon Neuroscience Se Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
WO2017172764A1 (en) * 2016-04-01 2017-10-05 The Regents Of The University Of California Modified cell line and method of determining tauopathies
KR101997319B1 (ko) 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
CA3047132A1 (en) * 2016-12-30 2018-07-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the detection of tau protein aggregates
EP3599842A4 (de) * 2017-03-21 2020-12-30 The Jackson Laboratory Genetisch veränderte maus, die humanes apoe4 und maus-trem2.p.r47h ausdrückt, und verfahren zur verwendung davon
BR112020018868A2 (pt) 2018-03-28 2021-01-26 Axon Neuroscience Se métodos baseados em anticorpo para detectar e tratar doença de alzheimer
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
AU2020325770B2 (en) 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
CN110679549B (zh) * 2019-11-05 2021-08-20 南通大学 一种阿尔茨海默病小鼠模型的构建方法
WO2023049871A2 (en) * 2021-09-24 2023-03-30 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
AU782281B2 (en) * 1999-07-02 2005-07-14 Janssen Pharmaceutica N.V. Transgenic animals as models for neurodegenerative disease
ATE326700T1 (de) * 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
WO2001053340A2 (en) * 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
WO2001065252A1 (en) * 2000-02-29 2001-09-07 The Nathan S. Kline Institute For Psychiatric Research Transgenic mice comprising a genomic human tau transgene
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation
DK1521774T3 (da) * 2002-07-12 2008-10-27 Axon Neuroscience Trunkerede Tau-proteiner

Also Published As

Publication number Publication date
DK1521831T3 (da) 2008-06-30
ATE391781T1 (de) 2008-04-15
US20100063250A1 (en) 2010-03-11
AU2003253044A1 (en) 2004-02-02
EP1521831A2 (de) 2005-04-13
JP4414332B2 (ja) 2010-02-10
JP2009143906A (ja) 2009-07-02
US20160106077A1 (en) 2016-04-21
DK1521774T3 (da) 2008-10-27
JP4308760B2 (ja) 2009-08-05
EP1521774A2 (de) 2005-04-13
US9485972B2 (en) 2016-11-08
US8288608B2 (en) 2012-10-16
EP1521774B1 (de) 2008-08-27
WO2004007547A3 (en) 2004-07-22
US20060112437A1 (en) 2006-05-25
EP1995255A1 (de) 2008-11-26
WO2004007722A3 (en) 2004-03-25
US9161520B2 (en) 2015-10-20
AU2003253044B2 (en) 2009-08-13
DE60320258T2 (de) 2009-06-25
US20060167227A1 (en) 2006-07-27
AU2003246664B2 (en) 2007-06-14
US20130179997A1 (en) 2013-07-11
ES2304146T3 (es) 2008-09-16
EP1521831B1 (de) 2008-04-09
WO2004007547A2 (en) 2004-01-22
ES2311734T3 (es) 2009-02-16
CN100572392C (zh) 2009-12-23
DE60320258D1 (de) 2008-05-21
CN100577803C (zh) 2010-01-06
JP2006515270A (ja) 2006-05-25
WO2004007722A2 (en) 2004-01-22
ATE406383T1 (de) 2008-09-15
CN1668641A (zh) 2005-09-14
AU2003246664A1 (en) 2004-02-02
CN1668745A (zh) 2005-09-14
JP2005532802A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
DE60323231D1 (de) Verkürzte tau proteine
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
EP2060585A3 (de) Gen-regulierende Peptide
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
ATE520981T1 (de) Diagnose und überwachung von krankheiten
ATE366259T1 (de) Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
CA2268029A1 (en) Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
DE60335726D1 (de) Chromoprotein und fluoroproteine
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE69836333D1 (de) Neisseria lactoferrin-bindendes protein
BRPI0308978A8 (pt) fragmentos de peptídeos sintéticos ativos
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
DE69712182T2 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE447045T1 (de) Assoziation von proteinpolymorphismen mit koronarer herzkrankheit
BRPI0621280A8 (pt) Polipeptídeo tendo atividade esterase e esterase recombinante e seus usos
WO2001000655A3 (en) Therapeutic peptides derived from subsequences of bpi
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification
WO2004058811A3 (en) Crystal structures of yhhf polypeptides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition